Table 1:
Patient characteristics in the resectable cohort of PDAC patients within the training and validation cohorts
| Characteristics | Training cohort | Validation cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | LAMC2 expression | Total | LAMC2 expression | |||||
| n = 121 | Low (n = 87) | High (n = 34) | P-valuea | n = 149 | Low (n = 90) | High (n = 59) | P-valuea | |
| Age, years | 0.27 | 0.52 | ||||||
| < 65, n (%) | 44 | 29 (33.3) | 15 (44.1) | 37 | 24 (26.7) | 13 (22.0) | ||
| ≥ 65, n (%) | 77 | 58 (66.7) | 19 (55.9) | 112 | 66 (73.3) | 46 (78.0) | ||
| Gender | 0.30 | 0.55 | ||||||
| Male, n (%) | 62 | 42 (48.3) | 20 (58.8) | 89 | 52 (57.8) | 37 (62.7) | ||
| Female, n (%) | 59 | 45 (51.7) | 14 (41.2) | 60 | 38 (42.2) | 22 (37.3) | ||
| Tumor status | 0.04b | 0.41b | ||||||
| T1–2 | 16 | 15 (17.2) | 1 (2.9) | 15 | 11 (12.2) | 4 (6.8) | ||
| T3–4 | 105 | 72 (82.8) | 33 (97.1) | 134 | 79 (87.8) | 55 (93.2) | ||
| Nodal status | 0.09b | 0.86 | ||||||
| N0 | 40 | 33 (37.9) | 7 (20.6) | 67 | 41 (45.6) | 26 (44.1) | ||
| N1 | 81 | 54 (62.1) | 27 (79.4) | 82 | 49 (54.4) | 33 (55.9) | ||
| UICC stage (ver. 7) | 0.13 | 0.49 | ||||||
| IA, IB | 14 | 13 (14.9) | 1 (2.9) | 11 | 9 (10.0) | 2 (3.4) | ||
| IIA | 25 | 20 (23.0) | 5 (14.7) | 54 | 31 (34.4) | 23 (39.0) | ||
| IIB | 67 | 45 (51.7) | 22 (64.7) | 68 | 40 (44.4) | 28 (47.5) | ||
| III, IV | 15 | 9 (10.4) | 6 (17.7) | 16 | 10 (11.2) | 6 (10.1) | ||
| CA19-9 (U/mL) | 0.60 | 0.49 | ||||||
| < 37, n (%) | 40 | 30 (34.5) | 10 (29.4) | 40 | 26 (28.9) | 14 (23.7) | ||
| ≥ 37, n (%) | 81 | 57 (65.5) | 24 (70.6) | 109 | 64 (71.1) | 45 (76.3) | ||
| Tumor size (mm) | 0.92 | 0.59 | ||||||
| < 40, n (%) | 93 | 69 (79.3) | 24 (70.6) | 120 | 73 (81.1) | 47 (79.7) | ||
| ≥ 40, n (%) | 27 | 18 (20.7) | 9 (26.5) | 16 | 11 (12.2) | 5 (8.5) | ||
| N/A | 1 | 1 (2.9) | 13 | 6 (6.7) | 7 (11.8) | |||
| Adjuvant therapy | 0.59 | 0.25 | ||||||
| Gemcitabine based | 80 | 58 (66.7) | 22 (64.7) | 92 | 59 (65.6) | 33 (55.9) | ||
| Other | 22 | 17 (19.5) | 5 (14.7) | 26 | 12 (13.3) | 14 (23.7) | ||
| none | 19 | 12 (13.8) | 7 (20.6) | 28 | 17 (18.9) | 11 (18.7) | ||
| Unknown | 0 | 0 | 0 | 3 | 2 (2.2) | 1 (1.7) | ||
a
Chi-square test
b
Fisher’s exact test
UICC, International Union Against Cancer; N/A, Not available